Hvilken er prisen på Metagenomi, Inc. Common Stock (MGX)

Prisen på Metagenomi, Inc. Common Stock (MGX) er $1.21

Hva er markedsverdien på Metagenomi, Inc. Common Stock (MGX)

Markedsverdien på Metagenomi, Inc. Common Stock (MGX) er $45.55M

Metagenomi, Inc. Common Stock (MGX) Utestående Aksjer

Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.

År	Utestående aksjer	Endre
Ikke nok data for de angitte datoene.

År

Utestående aksjer

Endre

Ikke nok data for de angitte datoene.

Selskap	Utestående aksjer	Forskjell	Land
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	-	US
Argenx SE ARGX.US	62.19M	-	NL
CSL Limited CSL.AX	483.58M	-	AU
Lonza Group AG LONN.SW	-	-	CH
Moderna, Inc. MRNA.US	396.00M	-	US

Selskap

Utestående aksjer

Forskjell

Land